1. 368TiPSTART: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306). (23rd October 2018) Authors: Bonnefoi, H; Levy, C; MacGrogan, G; Grellety, T; Asselain, B; Pulido, M; Everhard, S; Lemonnier, J; Gonçalves, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗